Swiss drugs regulator Swissmedic announced on Wednesday that it was "highly unlikely" that there was a link between the death of a 91-year-old person in the canton of Lucerne and the COVID-19 vaccine.
"Clarifications carried out by the cantonal health authorities and Swissmedic determined that as a result of the illness history and the course of disease that a link between the death and the COVID-19 vaccine was highly unlikely," the regulator said in a statement, adding that the deceased individual suffered from multiple previous illnesses.
No information was provided as to the time that had elapsed between the administration of the vaccine and the death of the individual concerned.
Pfizer responded to the death of the vaccine recipient, expressing condolences to the family of the deceased.
"It is important to note that serious adverse events, including deaths that are unrelated to the vaccine, are unfortunately likely to occur at a similar rate as they would in the general population of elderly and at-risk individuals who are currently being prioritized for vaccination," the company said, according to Reuters.
Pfizer on Tuesday announced it will supply an additional 100 million doses of its COVID-19 vaccine to the 27 European Union member states in 2021.
President Donald Trump urged states to hurry in administering the vaccine.